A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Brief description of study

This study is being done to answer the following question: what is the highest dose of CB-839 HCl (telaglenastat)that can be given safely (with manageable side effects) when adding the study drug to the usual treatment for your diffuse astrocytoma or anaplastic astrocytoma?We are doing this study because CB-839 HCl (telaglenastat)has not been previously used in combination with the usual approach, so we want to find the dose of CB-839 HCl (telaglenastat) that maximizes the benefit from the combination treatment for your diffuse astrocytoma or anaplastic astrocytoma. The study drug CB-839 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-01591
ClinicalTrials.gov Identifier: NCT03528642


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.